A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs GEN 003 (Primary) ; Matrix M
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences
- 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 Status changed from planning to not yet recruiting.